Stock Fundamentals

Company Information

Company Name
I-Mab
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US44975P1030
CIK: 0001778016
CUSIP: 44975P103
Currency: USD
Full Time Employees: 32
Phone: 240 745 6330
Fiscal Year End: December
IPO Date: Jan 17, 2020
Description:

I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Address:

2440 Research Boulevard, Rockville, MD, United States, 20850

Directors & Officers

Name Title Year Born
Mr. Wei Fu Executive Chairman 1982
Dr. Xi-Yong Fu M.B.A., Ph.D. CEO & Director 1972
Kyler Lei Chief Financial Officer NA
Mr. Tyler Ehler Senior Director of Investor Relations NA
Dr. Claire Xu M.D., Ph.D. Senior Vice President of Clinical Development NA
Dr. Phillip Dennis M.D., Ph.D. Chief Medical Officer 1963
Mr. Sean Wuxiong Cao M.B.A., Ph.D. Chief Business Development Officer & Independent Director NA

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Hillhouse Capital Advisors, Ltd. 5.98M Jun 30, 2025 7.32% $0.47 0.00%
Candriam Luxembourg S.C.A. 1.13M Jun 30, 2025 1.39% $0.02 0.00%
SG Americas Securities, LLC 876.35K Jun 30, 2025 1.07% $0.01 6.61%
Two Sigma Advisers, LLC 209.38K Jun 30, 2025 0.26% $0.00 -42.35%
UBS Group AG 184.85K Jun 30, 2025 0.23% $0.00 -41.97%
Aberdeen Group PLC 136.47K Jun 30, 2025 0.17% $0.00 -16.06%
BNP Paribas Arbitrage, SA 122.41K Jun 30, 2025 0.15% $0.00 1.24%
Two Sigma Investments LLC 113.26K Jun 30, 2025 0.14% $0.00 -46.16%
Ariose Capital Management Ltd 96.46K Jun 30, 2025 0.12% $0.15 0.00%
Alberta Investment Management Corp 74.72K Jun 30, 2025 0.09% $0.00 0.00%
Renaissance Technologies Corp 63.70K Jun 30, 2025 0.08% $0.00 -0.16%
Dimensional Fund Advisors, Inc. 58.36K Jun 30, 2025 0.07% $0.00 0.00%
Morgan Stanley - Brokerage Accounts 58.30K Jun 30, 2025 0.07% $0.00 67.43%
Geode Capital Management, LLC 54.56K Jun 30, 2025 0.07% $0.00 147.59%
Susquehanna International Group, LLP 37.54K Jun 30, 2025 0.05% $0.00 0.00%
Change Path, LLC 37.43K Jun 30, 2025 0.05% $0.00 0.00%
Barclays PLC 30.37K Jun 30, 2025 0.04% $0.00 0.00%
Mariner Wealth Advisors LLC 28.76K Jun 30, 2025 0.04% $0.00 0.00%
Connor Clark & Lunn Inv Mgmt Ltd 27.80K Jun 30, 2025 0.03% $0.00 0.00%
HRT FINANCIAL LLC 25.11K Jun 30, 2025 0.03% $0.00 57.03%

Shares Statistics

Shares Outstanding: 115.27M
Shares Float: 97.82M
% Insiders: 2,139.80%
% Institutions: 2,109.90%
Short % Float: 3.97%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Belfius Equities Cure C Cap 1.13M 1.39% ▲ 0.00% Aug 31, 2025
2 Fidelity Nasdaq Composite Index 54.56K 0.07% ▲ 0.41% Jul 31, 2025
3 abrdn Healthcare Opportunities 43.74K 0.05% ▲ 0.00% Jul 31, 2025
4 Dimensional Emerg Mkt Trgtd Val USD Acc 25.22K 0.03% ▲ 73.32% Jul 31, 2025
5 DFA Emerging Markets Social Core Port 18.91K 0.02% ▲ 0.00% Jul 31, 2025
6 DFA Emerging Markets Core Equity 2 I 16.22K 0.02% ▲ 0.00% Jul 31, 2025
7 DFA Em Mkts Sustnby Cor 1 Instl 9.31K 0.01% ▲ 0.00% Jul 31, 2025
8 ActivePassive International Equity ETF 8.12K 0.01% ▲ 0.17% Aug 29, 2025
9 Blackstone Alternative Multi-Strategy I 8.00K 0.01% ▼ 2.44% Dec 31, 2024
10 Dimensional World Equity GBP Acc 5.93K 0.01% ▲ 0.00% Jul 31, 2025

Valuation Metrics

Enterprise Value: $231.55M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $533.68M
EBITDA: $-38.09M
Book Value: $2.41
Earnings/Share: $-0.51
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -10.36%
ROE (TTM): -18.46%
Revenue (TTM): $3.49M
Revenue/Share (TTM): $0.04
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -62.10%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2024-12-31 20.90x 0.00x 0.05x N/A 0.00x
2023-12-31 5.67x 0.06x 0.34x -5,018.58x -0.32x
2022-12-31 5.50x 0.00x 0.26x -280,734.66x -0.12x
2021-12-31 7.66x 0.01x 0.19x -692.51x -0.01x
2020-12-31 9.28x 0.00x 0.11x 1,062.06x -0.16x
2019-12-31 2.31x -0.06x 2.17x -3,426.98x -0.63x
2018-12-31 5.88x -0.15x 1.40x -258.01x -0.34x
2017-12-31 3.54x -0.65x 1.29x -325.05x -0.70x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about IMAB.US!